journal logo

Welcome to Leukemia

Leading journal covering all aspects of the research and treatment of leukemia and allied diseases.

Announcements

  • collection image

    With this collection of Chronic Myeloid Leukemia (CML) related publications, we try to summarize current knowledge and address the most relevant research questions. OPEN FOR FURTHER SUBMISSIONS - Please contact the editorial office if you feel you have a relevant article for inclusion.

  • hero

    To improve understanding of the pheno/genotype abnormalities associated with cancer, tests have been developed to identify and quantify residual cancer cells undetected by conventional methods, with the hope of providing clinically meaningful predictive and/or prognostic data to inform therapy decision-making. This collection features critical analyses of the extent to which this has been achieved

  • emerging leaders

    This Emerging Leaders collection acknowledges and showcases the latest research from groundbreaking researchers, clinicians, and educators who are still in the early stages of their scientific careers.

Advertisement

leu collection image

Classification and nomenclature of hematologic diseases

The World Health Organization (WHO) Classification of Tumours provides a definitive classification of all tumours, worldwide. This is essential to underpin the diagnosis and treatment of cancer, as well as research and education. Without it, clinical trial results could not be compared between countries, research results could not be evaluated collectively and epidemiological studies based on cancer registration would be impossible. The classification will help move the field forward by being based on a forwardlooking multidisciplinary effort grounded in genetic advances, with an eye on worldwide applicability. An overview of the classification and its salient features are provided in two typescripts, which cover the classification of myeloid and histiocytic/dendritic neoplasms and the classification of lymphoid neoplasms. Added to this is the recent 'HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions'. In this typescript a group of experts under auspices of the Human Genome Organization’s (HUGO) Gene Nomenclature Committee (HGNC) proposes using double colons (::) as the official designation for fusion genes. The Leukemia Editors strongly support the HGNC recommendation and request authors use the HGNC nomenclature in submissions to Leukemia and other journals. The goal of HUGO and HGNC is to provide unique symbols and names for human gene loci including protein coding genes, non-coding RNA genes and pseudogenes with the purpose of unambiguous scientific communication.
Collection

Advertisement